Astria Therapeutics, Inc. Stock price

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
13.6 USD +0.52% Intraday chart for Astria Therapeutics, Inc. -13.49% +77.08%
Sales 2024 * - Sales 2025 * - Capitalization 747M
Net income 2024 * -79M Net income 2025 * -101M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-8.79 x
P/E ratio 2025 *
-6.91 x
Employees 59
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.7%
More Fundamentals * Assessed data
Dynamic Chart
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating MT
Transcript : Astria Therapeutics, Inc. - Special Call
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE CI
North American Morning Briefing : Markets on Hold -2- DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering MT
Astria Therapeutics Files $500 Million Mixed Shelf MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating MT
Transcript : Astria Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms DJ
More news

Latest transcript on Astria Therapeutics, Inc.

1 day+0.52%
1 week-13.49%
Current month-4.36%
1 month-2.72%
3 months+73.03%
6 months+62.68%
Current year+77.08%
More quotes
1 week
12.83
Extreme 12.83
16.90
1 month
12.51
Extreme 12.51
16.90
Current year
6.58
Extreme 6.58
16.90
1 year
4.26
Extreme 4.26
16.90
3 years
2.36
Extreme 2.36
17.76
5 years
2.36
Extreme 2.36
58.56
10 years
2.36
Extreme 2.36
1 017.60
More quotes
Managers TitleAgeSince
Founder 56 08-06-25
Director of Finance/CFO 51 11-03-31
Chief Tech/Sci/R&D Officer - 22-07-14
Members of the board TitleAgeSince
Chairman 73 13-12-31
Director/Board Member 65 19-01-03
Director/Board Member 75 16-04-04
More insiders
Date Price Change Volume
24-03-27 13.6 +0.52% 1,537,022
24-03-26 13.53 -8.27% 1,821,338
24-03-25 14.75 -2.51% 4,508,707
24-03-22 15.13 -5.38% 539,887
24-03-21 15.99 +1.72% 1,395,285

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.6 USD
Average target price
25.57 USD
Spread / Average Target
+88.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Astria Therapeutics, Inc. - Nasdaq